Faecal Calgranulin C Versus Faecal Calprotectin as Non Invasive Markers Distinguishing Functional From Organic Causes of Chronic Diarrhea
Mohammed Amin Mohammed,
Alaa Mahamad A. Hakeem El-Gamal,
Nesreen Moustafa Omar,
Abdelhadi M. Shebl,
Amany H. Mansour,
Sherin Mohamed Abd El-Aziz,
Soad Amin Mohammed
The major challenge in inflammatory bowel disease is to achieve a sensitive
and specific non invasive diagnostic marker. Recently, S100A12 (Calgranulin
C) have been established to be elevated in the feces of patients with IBD. The
objective was to investigate the utility of fecal S100A12, in comparison to
fecal Calprotectin and standard inflammatory markers, as a screening and distinguishing
marker for IBD and Irritable Bowel Syndrome (IBS) in patients with chronic diarrhea.
Stool samples were obtained from 173 individuals presenting with gastrointestinal
symptoms requiring endoscopy. Fecal S100A12, fecal Calprotectin and serum S100A12
levels were measured and correlated to final diagnosis and standard tests (ESR,
CRP, platelet count, albumin, perinuclear anti-neutrophil and antineutrophil
cytoplasmic antibodies. Full colonoscopy with histopathological examination
was performed. Patients diagnosed with IBD had elevated fecal S100A12 (median
49.7 mg kg-1) and Calprotectin (median 385 mg kg-1) levels
compared with the patients without IBD (n = 35, S100A12: Median 4.6 mg kg-1,
p<0.0001, Calprotectin: Median 30.5 mg kg-1; p<0.0001). Both
the sensitivity and specificity of fecal S100A12 (cutoff 8 mg kg-1)
for the detection of IBD were 93.91 and 97%, respectively whereas fecal Calprotectin
(cutoff 35 mg kg-1) gave a sensitivity of 93.96% and a specificity
of 84.2%. Both fecal markers were superior to the sensitivities and specificities
of any standard inflammatory test. Both fecal S100A12 and Calprotectin are sensitive
markers of gastrointestinal inflammation but fecal S100A12 provided exceptional
specificity in distinguishing patients with IBD from patients without IBD.
to cite this article:
Mohammed Amin Mohammed, Alaa Mahamad A. Hakeem El-Gamal, Nesreen Moustafa Omar, Abdelhadi M. Shebl, Amany H. Mansour, Sherin Mohamed Abd El-Aziz, Gamal Othman and Soad Amin Mohammed, 2014. Faecal Calgranulin C Versus Faecal Calprotectin as Non Invasive Markers Distinguishing Functional From Organic Causes of Chronic Diarrhea. Journal of Medical Sciences, 14: 179-191.
Received: January 17, 2014;
Accepted: April 10, 2014;
Published: June 24, 2014
Inflammatory Bowel Disease (IBD) consisting mainly of Ulcerative Colitis (UC) and Crohns Disease (CD) is chronic idiopathic inflammatory condition of the gut with a typically remitting and relapsing course characterized by symptoms of abdominal pain, diarrhea, urgency of defecation and occasionally rectal bleeding. Treatment goal is to induce and maintain disease remission (Hanauer, 2006). The diagnosis and differentiating IBD patients from those with Irritable Bowel Syndrome (IBS) represents the major challenge to gastroenterologists. The IBD can be challenging to diagnose and fecal markers of disease that correlate with its severity could potentially be clinically useful. The etiology of Inflammatory Bowel Disease (IBD) involves complex interactions among susceptibility genes, the environment and the immune system. These interactions lead to a cascade of events that involve the activation of neutrophils, production of pro-inflammatory mediators and tissue damage (Hanauer, 2006).
Although, all studied faecal biomarkers provide reliable and simple non invasive means in the differentiation of IBD and IBS, Calprotectin appears to represent the most accurate marker to discriminate these two common causes of chronic diarrhea (Schroder et al., 2007). Endoscopic examination and histological analysis of biopsy specimens remain the "gold standard" methods for detecting and quantifying bowel inflammation.
As intestinal symptoms are a frequent cause of referrals to gastroenterologists, it is mandatory to differentiate between IBD and non-inflammatory Irritable Bowel Syndrome (IBS). The natural history of IBD is characterized by an unexpected variation in the degree of gut inflammation. The gold standard methods for detecting and quantifying bowel inflammation still remain the invasive endoscopic manoeuvres and histological analysis of biopsy specimens, however, these techniques are costly, invasive and repeated examinations are unpopular with patients. Disease activity questionnaires and the widely used laboratory inflammatory markers are unreliably correlated with endoscopy and histopathology. Anti-Saccharomyces Cerevisiae Antibody (ASCA) and atypical Perinuclear Antineutrophil Cytoplasmic Antibody (P-ANCA) are the most widely studied serologic markers and remain the best characterized markers in IBD. As these serum inflammatory markers are non specific, can be elevated in a variety of conditions, new more specific fecal markers are needed for detecting and quantifying bowel inflammation (Pardi and Sandborn, 2005).
To date, there is a paucity of biological markers to determine intestinal inflammation (Vermeire et al., 2006; Niederau et al., 1997). Biological markers are needed to confirm disease remission, detect early relapses and to monitor reliably anti-inflammatory therapies. Serum markers of gut inflammation are still not very useful in determining intestinal inflammation (Brignola et al., 1986; Nielsen et al., 2000). While, assays that detect neutrophil-derived products in stool show great promise in this issue (Langhorst et al., 2005).
The members of the S100 protein family are all calcium-binding proteins and exhibit a dimeric nature. To our knowledge, 25 tissue and cell-specific S100 proteins have been recognized to date in humans. It is thought that S100 proteins carry out a series of proposed biological tasks, such as regulation of protein phosphorylation, modulation of enzyme activity, promotion of cell growth, differentiation or apoptosis, participation in Ca++ homeostasis, preservation of cell shape and motility, regulation of coagulation and induction of proinflammatory/inflammatory responses (Santamaria-Kisiel et al., 2006).
Initiation and perturbation of inflammation in IBD is mainly through activation of innate immune mechanisms. Certain S100 proteins, S100A8/A9 heterodimer (Calprotectin), S100A12 (calgranulin C) have been identified to be released by infiltrating neutrophils during cell activation and lysis (Foell et al., 2007). These proteins of the S100 family proved to have quite emerging trigger for intense research towards their involvement in many different inflammtory, malignant and degenerative diseases (Salama et al., 2008). Also, these S100 proteins have been linked with both digestive and extra-digestive disorders, including IBD. There are multiple emerging evidences focusing on their role in the pathogenesis activity, diagnosis and therapeutic management of IBD (Foell et al., 2003a; Donato, 2003). Apart from inflammation, certain S100 proteins have also been suggested to have a crucial role in alimentary tract-related tumorigenesis (Moskaluk et al., 2002).
Calprotectin, a 36 kDa calcium and zinc binding protein, is detectable both in the serum and stool during intestinal inflammation and may probably be the most promising marker for IBD. It represents 60% of cytosolic proteins in granulocytes. The presence of Calprotectin in faeces can therefore be considered directly proportional to neutrophil migration to the gastrointestinal tract (Vermeire et al., 2006; Roth et al., 2003). Recently fecal Calprotectin has been proposed as a faecal marker of gut inflammation reflecting the degree of phagocyte activation (Sherwood, 2012; Manolakis et al., 2011).
However, variations in faecal Calprotectin assays still restrain its routine use as a sole parameter in clinical practice. The broad expression pattern of Calprotectin in granulocytes as well as monocytes, macrophages and epithelial cells is responsible for these observed variations (Foell et al., 2004; Campeotto et al., 2004).
In contrast with Calprotectin, S100A12 is more restricted and predominantly expressed in granulocytes. It is abundantly secreted by the activated infiltrating neutrophils in the intestinal mucosa of patients with IBD (Vogl et al., 1999). Overexpression at the site of inflammation and correlation with disease activity in a variety of inflammatory disorders affirm the role of this granulocytic specific protein as a proinflammatory molecule (Kaiser et al., 2007). The S100A12 promotes gut inflammation through long-term activation of Nuclear Factor kappa B (NF-κB) via binding to the Receptor for Advanced Glycation End-products (RAGE) (Hofmann et al., 1999). In experimental studies, (mouse models of colitis), blocking the interaction of S100A12 with RAGE proved to attenuate gut inflammation confirming the crucial role for S100A12 in pathogenesis of these disorders (De Jong et al., 2006). The S100A12 is overexpressed during chronic active IBD and serves as a useful serum marker for disease activity in patients with IBD (Foell et al., 2003b). De Jong et al. (2006) reported that S100A12 can be detected in the stool of children with Crohns disease.
We investigated the utility of fecal S100A12, in comparison to fecal Calprotection and standard inflammatory markers, as a screening and distinguishing marker for IBD and IBS patients with chronic diarrhea.
The correlation of Fecal S100A12 and Calprotectin levels with endoscopic and histological findings in participants were also studied.
MATERIALS AND METHODS
Subjects: A total of 173 adult consecutive subjects, older than 20 years, with gastrointestinal symptoms requiring endoscopy and 35 age and sex-matched healthy subjects were initially enrolled in this prospective study from January 2012 through 2014. This study, in agreement of the World Medical Association (WMA) of Helsinki declaration (WMA, 1964), was approved by the Ethical Commission and Institutional Review Board of Mansura University Hospital in Egypt. A written informed conscious consent was obtained from all patients before their participation. Initially, all patients completed a detailed questionnaire regarding diet and habits, submitted to thorough history taking with special emphasis on abdominal pain, weight loss, rectal bleeding, diarrhea, constipation, malaise, lethargy, anorexia, nausea, tenesmus, abdominal distension, passage of mucous, vomiting and low-grade fever along with detailed physical examinations performed at fasting in the morning.
Exclusion criteria: Patients with incomplete ileocolonoscopy, past history of any malignant condition and major gastrointestinal surgical procedures, liver cell failure, coagulopathy, chronic renal failure, urinary incontinence (contaminate the stool samples), congestive heart failure, endocrinal diseases (diabetes, thyroid disease), cardiopulmonary diseases, immune-compromised patients or on chemotherapy, advanced chronic or psychiatric illness, pregnancy, smokers, drug or alcohol abuse, Non Steroidal Anti-Inflammatory Drugs (NSAIDs), aspirin intake and any special type of dieting or treatments for the previous 6 months were excluded from the study. Eight patients were excluded and the remaining 200 participants underwent routine laboratory and radiological investigations and gastrointestinal endoscopic evaluation at enrollment.
Endoscopy: Upper endoscopy (distal duodenum), total colonoscopy and ileoscopy (distal ileum) (a gastroscope/ colonoscope; XQ40, Pentax Fiberoptic, Tokyo) performed after overnight fast and/or cleansing enemas between 08:00 and 10:00 am. The macroscopic endoscopic features of mucosa were evaluated and multiple biopsies were taken from distal duodenum, colon or ileum (from both diseased and healthy areas) for histopathological examination which is the gold standard to detect and quantify IBD (asses the severity and extent of endoscopic findings). The macroscopic endoscopic signs of inflammation were recorded by the experienced gastroenterologist using the Simplified Endoscopic Activity Score for CD (SES-CD) (Daperno et al., 2004) or Rachmilewitz endoscopic score for ulcerative colitis (Rachmilewitz, 1989). These macroscopic endoscopic features may be, normal endoscopic signs, active ulcerative colitis, active Crohns disease, celiac disease, diverticula with peri-diverticular inflammation, ischemic colitis, colorectal cancer or polyps and miscellaneous diagnoses.
Histopathological determination of disease activity: The 135 patients confirmed to have IBD to define inflammatory activity in the gut, in addition to endoscopic features, multiple biopsies were taken from different sites, embedded in Paraffin blocks, sectioned and stained with hematoxylin and eosin for conventional histopathological examination. Biopsy sections were encoded and analyzed semiquantitatively on a four-point scale (0, 1, 2, 3; non, mild, moderate and severe inflammation, respectively) by two independent histopathologists, who were blinded to the diagnosis and clinical data. The neutrophilic infiltration in the lamina propria and epithelium was graded as absent, mild, moderate, or severe according to the updated Sydney system (Dixon et al., 1996). As a further inclusion criterion, the histology score had to be in accordance with endoscopic signs of inflammation. This histology inflammation score served as the reference standard to determine the absence of inflammation or active IBD in this study cohort. Celiac disease diagnosed according to Modified Marsh Classification (Oberhuber, 2000; Marsh, 1992).
In addition, clinical disease activity in CD was documented according to the Crohns Disease Activity Index (CDAI) (Best et al., 1976) and for ulcerative colitis by using the Colitis Activity Index (CAI) of Rachmilewitz (1989). Levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count, platelets, hemoglobin and hematocrit were determined in all patients. Inflammatory Bowel Disease (IBD) patients were considered inactive if there were no endoscopic and histological signs of inflammation (histology inflammation score<1) and normal disease activity scores (CDAI<150; CAI<6). In addition, extra-intestinal disease and small bowel involvement were excluded in Crohns disease patients by clinical examination and contrast enhanced Magnetic Resonance Imaging (MRI) using the Sellink technique (Ajaj et al., 2005).
The fifty eight patients who have infectious gastroenteritis, in addition to clinical presentation, were confirmed by microbiological stool examination, including classic culture methods for enteropathogenic bacteria and the detection of enteropathogenic viruses according to standard procedures. In patients with acute gastroenteritis stool was collected in regular sterile sample containers and sent to the laboratory within 24 h.
Thirty five patients with IBS fulfilled the ROME III criteria (Tibble et al., 2002). Symptoms suggesting gastrointestinal inflammation in IBS included straining during bowel movement, the passage of mucus, weight loss and fatigue. Endoscopic and histopathological evaluations of these patients negate IBD. The ROME III, criteria for IBS: Symptoms of recurrent abdominal pain or discomfort (uncomfortable sensation not described as pain) and a marked change in bowel habit for at least six months, with symptoms experienced on at least three months. Two or more of the following must apply: Pain is relieved by a bowel movement, onset of pain is related to a change in stool frequency, onset of pain is related to a change in stool appearance.
Healthy controls: The control group comprised 35 age and sex-matched healthy subjects (volunteers, medical students and health workers) without any signs of inflammation or intestinal symptoms. They supplied a single stool sample after giving informed consent.
Laboratory investigations: Eight milliliters of whole blood were collected onto 3 tubes, 3 mL on EDTA for CBC and ESR, 2 mL of blood were collected onto citrate for immediate assay of P.T and P.T.T and lastly 3 mL blood was collected into plan tube, prompt separation of serum was done for assay of fasting blood glucose, kidney and liver function tests, electrolytes and CRP. Part of serum was stored at -200°C until assay of ASCA and P-ANCA. Another sample was withdrawn after two hours for assay of postprandial blood glucose.
Complete blood count was performed using coulter B66, Miami, Florida, USA, liver function tests including total protein, serum albumin, AST, ALT, total and direct serum bilirubin and kidney function tests including serum creatinine, blood urea nitrogen as well as electrolytes (Na and K) and glucose were all done on Synchron CX9 autoanalyzer (Brea, California, USA), P.T and P.T.T using coagulometer. Quantitative CRP was done using nephelometry, complete stool analysis and stool culture: To affirm the presence or absence of infectious gastroenteritis.
Calprotectin and S100A12: The whole stool specimens were collected by the patients 72 h before endoscopy (before starting bowel preparation). A single stool sample (about 5 g weight) placed in a suitable disposable plastic bucket-type device that avoids toilet water artifact and simplifies laboratory sampling were frozen to -70°C immediately after collection and sent to the laboratory. Calprotectin is stable in the feces at room temperature for at least 72 h and for more than 6 months when frozen. Avoid repeated freeze-thaw cycles. About 100 mg of the faecal sample were added to 4.9 mL of diluted (at 1:50 dilution) extraction buffer solution in a screw cap tube which was then shaked vigorously for 30 sec by means of a vortex mixer then homogenized 30 min on a shaker or roller as described previously (Langhorst et al., 2005; De Jong et al., 2006). One milliliter of the homogenate was transferred to an Eppendorf tube and centrifuged at 10000 rpm for 20 min. Then 0.5 mL of the clear extract supernatant was transferred to another eppendorf tube and was stored at -80°C until analysis for both Calprotectin and S100A12. The analyses for these markers were performed using aliquots from identical samples. Samples were prepared and analyzed in accordance following manufacturers instructions.
The concentrations of S100A12 (either fecal or serum) were determined by a double sandwich ELISA system as described previously (Foell et al., 2003a). The inter-assay and intra-assay CV% were 12.1 and 4.8%, respectively.
Faecal Calprotectin was determined by a commercially available ELISA kit (Calpro AS, Oslo, Norway) following the manufacturer's instructions. The inter-assay and intra-assay CV% were 4.3-5.3 and 6.1-8.7%, respectively. The value of the normal range is 5-50 mg kg-1. The readers of the laboratory assay were blinded to the clinical data and diagnosis.
IBD antibodies (ASCA and P-ANCA) were detected in the first group only. The ASCA (IgA and IgG) detection were done by the QUANTA-Lite ELISA assay (Inova Diagnostics, San Diego, CA) as described elsewhere (Seibold et al., 2001) while atypical P-ANCA detection was done by indirect immunoflouresence (Inova Diagnostics, San Diego, CA/EuroImmun, Germany) as described elsewhere (Seibold et al., 1992). The CD markers were defined as ASCA+ve/P-ANCA-ve or ASCA+ve/P-ANCA+ve and the UC markers as P-ANCA+ve/ASCA-ve (Papp et al., 2007).
Data was analyzed using SPSS software (Version 17.0). Quantitative data was expressed as (Mean±SD) while qualitative data was expressed as number and percentage. The qualitative or categorical variables were described as proportions. Proportions were compared using the chi-squared test or Fishers exact test whenever applicable. Subgroups were compared by using the McNemar test. Continuous data are expressed as median (range) and were evaluated by appropriate statistical tests. Mann-Whitney U-test was used for the continuous ordinal data between two qualitative variables. Comparisons between the groups were performed using the Students t-test whenever applicable. Kruskal-Wallis, one way analysis of variance (ANOVA) compared more than two groups. A value of p<0.05 was considered statistically significant. Correlations between fecal markers and other variables were evaluated using the Spearman rank correlation coefficient test. Variables that achieved statistical significance with the univariate analysis were included in multiple regression analysis to evaluate the independent factors associated with high fecal Calprotectin or Calgranulin C. Sensitivity, specificity and predictive values were calculated to study the overall predictability of other techniques according to the following equations:
Positive (+ve) predictive value = (N0 of true +ve cases/N0 of all +ve cases with screening test)x100
Negative (-ve) predictive value = (N0 of true -ve cases/N0 of all -ve cases with screening test)x100
Sensitivity = (N0 of true +ve cases/N0 of all +ve cases with reference test)x100
Specificity = (N0 of true -ve cases/N0 of all -ve cases with reference test)x100
Overall predictability (accuracy) = (N0 of true +ve and true -ve cases/total N0 of all +ve and all -ve cases) x100
A total of 173 patients presented with gastrointestinal symptoms in outpatient clinic and 35 age and sex-matched healthy volunteers (Control group) underwent specific laboratory, radiological investigations and diagnostic upper and lower endoscopy. The Flow chart of the study and distribution of diseases in all studied populations were shown in Fig. 1. Eight patients were excluded; three with chronic liver disease, two with previous major gastrointestinal surgery and three with cardiopulmonary disease. From the remaining 165 studied patients, 135 patients were confirmed to have IBD, 38 with UC, 27 with CD, 3 with celiac disease, 4 with diverticulitis and 58 patients with infectious gastroenteritis (GE). The remaining 35 patients fulfilled the ROME III criteria and had IBS.
The characteristics of control and patients groups either organic (IBD; UC or CD) or non-organic (IBS) GIT diseases were mentioned in Table 1. Most of IBS patients were female gender (IBS more common in female). There was statistically significant difference between studied IBD, IBS and control groups as decreased hemoglobin and serum albumin levels, elevated white blood cells (although its value was within normal ranges), elevated ESR and CRP as markers of inflammation and occurrence of bleeding per rectum in IBD group (ANOVA = 0.0001). Also, there was a remarkably statistically significant difference between patients with IBD versus either patients with non organic diseases (IBS) or healthy control as regards fecal Calprotectin and fecal S100A12 levels being highly elevated in IBD group (ANOVA = 0.0001). On the other hand, no significant differences were demonstrated between IBS and Control groups (p = 0.0001) in any parameter.
||Distribution of diseases in all studied populations (n = 208)
|Table 1:|| Demographic data, clinical, serological and fecal characteristics of the studied groups
|IBD: Inflammatory bowel disease, IBS: Irritable bowel syndrome, HC: Healthy control, UC: Ulcerative colitis, CD: Crohns disease. ANOVA compared IBD: IBS and control groups, P1-value: Compared IBD and IBS subgroups, P2-value: Compared IBD and control subgroups, P3-value: Compared IBS and control subgroups, Significance at the value ≤0.05|
The patient's characteristics of ulcerative colitis and Crohn's disease were demonstrated in Table 2. No significant differences were observed between the two sets of patients (UC or CD) regarding demographic, clinical, serological and histopathological characteristics (p = 0.05). The majority of patients (19/21) with ASCA-/pANCA+ were confirmedly diagnosed as UC compared with only two who diagnosed as CD. On the other hand, the majority of patients (17/19) with ASCA+/pANCA+ or ASCA+/pANCA- were confirmedly diagnosed as CD compared with only two who diagnosed as UC. Twenty five patients were ASCA-/pANCA- (UC/CD; 17/8).
The correlations between fecal markers (fecal S100A12 and fecal Calprotectin) and other parameters in patients with IBD were demonstrated in Table 3. Both fecal S100A12 and fecal Calprotectin were significantly positively correlated with duration, chronicity and severity of the IBD, increased frequency of diarrhea, occurrence of bleeding per-rectum, increased inflammatory markers as ESR and CRP, elevated WBC count and increased platelets and increased pulse rate (p≤0.05). Moreover, both fecal markers were significantly positively correlated with clinical disease activity indices (CAI and CDAI), endoscopic scores (Rachmilewitz and SES-CD) and histology inflammation score (p≤0.05). Also, fecal S100A12 was significantly positively correlated with fecal Calprotectin (p≤0.05). Contrary, fecal S100A12 and fecal Calprotectin were significantly negatively correlated with hemoglobin level (p<0.001) and serum albumin (p≤0.05). Such correlations were not observed regarding age, sex, ASCA, P-ANCA and CMV (p<0.05).
The effect of disease location on fecal S100A12, fecal Calprotectin and other inflammatory markers in patients with inflammatory bowel disease were shown in Table 4 and Fig. 2. All test markers performed equally well regardless the disease location. However, the test for fecal Calprotectin was significantly higher in case of colonic involvement.
|| Demographic data, clinical, serological and fecal characteristics features of patients with inflammatory bowel diseases
|CAI: Colitis activity index, CDAI: Crohn's disease activity index, ASCA: Anti-Saccharomyces cerevisiae antibody, SES-CD: Simple endoscopic score for Crohn's disease, P-ANCA: Peri-nuclear anti-neutrophil cytoplasmic antibody|
|Table 3:|| Spearmanrho correlations between fecal S100A12 and fecal Calprotectin and other parameters in patients with inflammatory bowel disease
|*Correlation is significant if p≤0.05 (2-tailed)|
The linear regression analysis of fecal S100A12 and fecal Calprotectin to other parameters was demonstrated in Table 5. High level of fecal S100A12 as well as fecal Calprotectin could predict presence of high pulse rate, increased frequency of diarrhea, occurrence of bleeding per-rectum, high WBC and platelets count, low level of hemoglobin, low serum albumin, high CRP and ESR and more colonic involvement. Moreover, high level of both fecal markers could significantly predict higher clinical disease activity indices (CAI and CDAI), endoscopic scores (Rachmilewitz and SES-CD) and histology inflammation score (p = 0.05).
|Table 4:|| Fecal (S100A12 and Calprotectin) and other inflammatory markers in patients with inflammatory bowel disease according to disease location
|Table 5:|| Linear regression analysis of fecal S100A12 and fecal Calprotectin to other parameters in patients with inflammatory bowel disease
|Significant if p≤0.05|
|Table 6:|| Diagnostic accuracy of fecal and other markers in distinguishing active inflammatory bowel disease from irritable bowel syndrome and healthy control
|PPV: Positive predictive value, NPP: Negative predictive value, AUC: Area under the curve, 95% CI: 95% confidence interval|
Also, high level of fecal S100A12, significantly predicted high level of fecal Calprotectin (p≤0.05).
The diagnostic accuracy of fecal S100A12 and fecal Calprotectin and other markers in distinguishing IBD from IBS and healthy control were shown in Table 6. Cutoff points of 8 μg g-1 and 35 μg g-1 for fecal S100A12 and fecal Calprotectin, respectively were used to distinguish active IBD from IBS and healthy controls. Both fecal biomarkers (S100A12 and Calprotectin) were found to distinguish between IBD and IBS with almost equal sensitivity (~94%) but with higher specificity for fecal S100A12 (97% vs. 84.2% for fecal Calprotectin) and higher diagnostic accuracy (96.1% vs. 92.6%). The test accuracy indicated by sensitivity, specificity, PPV, NPP and odd ratio was superior for fecal S100A12 compared to any other marker.
Fecal markers in patients with inflammatory bowel disease in relation to disease location
Receiver Operating Characteristics (ROC) curve for fecal Calprotectin and fecal S100A12 in differentiating patients with inflammatory bowel disease from those with irritable bowel syndrome and healthy control
Other markers including ESR, CRP, CDAI and CAI had much less diagnostic accuracy than fecal markers.
The receiver operating curve analyses was performed and demonstrated in Fig. 3 to determine cut off points for fecal markers measurements. Both fecal biomarkers (S100A12 and Calprotectin) were found to distinguish IBD from IBS and healthy control with a better result for faecal S100A12 (AUC: 0.983, 95% CI: 0.897-0.998) than for fecal Calprotectin (AUC: 0.797, 95% CI: 0.669-0.885).
Various types of organic (IBD) and non organic (IBS) GIT disorders may have similar symptoms and clinicians suffer a lot in differentiating between the two categories especially the management is completely different and the clinical examination alone may not be sufficient to give a specific diagnosis. Since the proposed methods assessing bowel inflammation are nonspecific, complex and expensive or expose the patient to pain, ionizing radiation or other risks, there is a need for a simple, inexpensive, non invasive and objective method helping in screening and selecting patients for further additional investigation, for instance endoscopy and biopsy.
Damage to gastrointestinal mucosal layer occurred in most of organic GIT disorders like IBD vary from increased permeability to ulceration. Such injury provokes polymorphonuclear neutrophillic (PMN), granulocyte infiltration and migration to gut lumen where their contents either leaked or are released including Calprotectin and S100A12 proteins (Foell et al., 2007).
Faecal estimation of these protein cytokines and markers of neutrophil activation in intestinal inflammation is attractive and promising in the clinical routine as they could provide a non-invasive examination that can help screening patients with mild GIT symptoms and may have roles in discriminating IBD from IBS. Moreover, their measurement could be helpful in follow up inflammation and early detection of relapse or subclinical activity (Pardi and Sandborn, 2005).
Lactoferrin, myeloperoxidase (MPO) and polymorphonuclear (PMN) elastase are faecal markers of neutrophil degranulation but are not expressed in neutrophils only and are of limited stability in stool samples. Other markers of neutrophil-derived proteins, lysozyme or human neutrophil lipocalin are less promising (Peterson et al., 2002).
Recently, neutrophil-derived S100 proteins have been identified and extensively investigated as faecal markers distinguishing IBD from IBS. S100 proteins [S100A8/A9 (Calprotectin), S100A12 (Calgranulin C)] are cytosolic molecules released by activated or damaged cells during cell stress and have a remarkable stability in stool samples in room temperature (resist degradation by faecal bacteria) making them suitable markers for gut inflammation (Foell et al., 2009).
As expected and as these proteins are expressed by infiltrating granulocytes, their fecal levels are significantly higher in IBD than in IBS. However, some conflicts about their levels in active disease compared with inactive IBD had been observed (Sugi et al., 1996). The most extensively investigated faecal marker is Calprotectin (S100A8/S100A9 complex). In many previous studies, fecal Calprotectin has been claimed to be a specific, sensitive, non-invasive, cheap and accessible biomarker for gut inflammation that correlates well with disease activity in IBD and can distinguish IBD from IBS with a reported sensitivity varies between 65% and 95% and specificity between 75% and 91%, (Langhorst et al., 2005; Foell and Roth, 2005; Judd et al., 2011).
In the IBD, many symptoms are similar to the functional disorder IBS. Thus the major challenge is to distinguish symptoms of IBD from IBS. In this study, fecal Calprotectin can also significantly differentiate organic gastrointestinal diseases including IBD from non organic disorders including IBS patients with an overall diagnostic accuracy of 92.6%. The results obtained in this study for fecal Calprotectin are therefore within the range found in previous studies. In a previous study, Calprotectin levels were elevated in subgroups of IBD patients that are in remission and have coexisting IBS-like symptoms and can still differentiate IBD from IBS (Jelsness-Jorgensen et al., 2013).
The observed variations of Calprotectin results could be explained by variable presentation of epitopes on the Calprotectin complex under different conditions and the broad expression pattern of Calprotectin induced in epithelial cells under certain circumstances influencing the results (Foell and Roth, 2005).
Also, faecal Calprotectin have been elevated in bacterial enteritis and rotavirus infections (Judd et al., 2011). In contrast, faecal S100A12 was not elevated in viral gastroenteritis as was faecal Calprotectin and lactoferrin. Collectively, fecal S100A12 biomarker is more specific for neutrophils than Calprotectin and neutrophil activation is less involved in viral gastroenteritis than in bacterial infections.
Patients with IBD were significantly presented by high pulse rates although within normal value, high ESR and CRP, high WBC count, bleeding per rectum and high fecal Calprotectin level. Similarly, Xiang et al. (2008) found that patients with active UC had higher levels of CRP and ESR than patients with inactive UC and control group. This could be explained by the fact that these parameters are elevated in many systemic inflammatory conditions as acute phase reactant. The CRP is one of the many acute phase proteins that increase in the serum of patients with active IBD. It is more sensitive in cases of CD than UC but not specific for gut inflammation. So, the use of CRP and ESR only to identify patients with IBD that need further evaluation would retard the diagnosis of many cases.
S100A12 is almost exclusively expressed in large amounts by granulocytes which play a crucial role in pathogenesis of IBD and does not form heterodimers with S100A8 or S100A9. It is secreted exclusively by activated neutrophils and promotes inflammation through Receptor for Avanced Gycation Edproducts (RAGE) activation (Schmidt et al., 2001; Dabritz et al., 2014). The neutrophil influx into the intestinal mucosa is closely related to IBD activity and inflammation. Therefore, neutrophil-derived S100A12 in tissues and exudates strongly correlates with inflammatory activity. Moreover, the excretion of this protein into the gut lumen could reflect the number and activation status of infiltrating neutrophils (Foell et al., 2003b). Fecal S100A12 measurement is specific for neutrophil activity during bowel inflammation but is not strictly disease specific. Recently, it was reported that S100A12 is detectable in stool samples, where it is evenly distributed and is as stable as Calprotectin for up to 7 days (De Jong et al., 2006).
In the current study, a strong significant correlation between fecal biomarkers (Calprotectin and S100A12) and intestinal inflammation confirmed either endoscopically (SES-CD or Rachmilewitz Endoscopic score for UC) or histologically. In contrast, a number of studies have found clinical and endoscopic scores to be of little value in monitoring of disease activity.
In this study, faecal S100A12 was demonstrated to discriminate between IBD and IBS with high diagnostic accuracy and significantly distinguish active from inactive disease and even could differentiate UC from CD. Moreover, the test for faecal S100A12 performs equally well regardless of disease location. These findings are analogous to Calprotectin which is also more accurate in ulcerative colitis (Costa et al., 2005). De Jong et al. (2006) reported similar results. The present study also confirm the fact that neither faecal marker of intestinal inflammation is completely specific for IBD but rather for intestinal inflammation in general, because the levels of these phagocyte-derived proteins are also elevated during infectious gastroenteritis. In this regard, S100A12 as a specific marker of neutrophil activation may be useful in monitoring disease activity.
In the present study, the histology inflammation score was the gold standard for diagnosis. Faecal S100A12 strongly correlates with intestinal tissue inflammation suggesting that the infiltrating neutrophils are the main source of faecal S100A12. Kaiser et al. (2007) found that immunohistochemical staining of tissue sections confirmed S100A12 expression in the gut of patient with active IBD more than inactive disease and IBS confirming that infiltrating neutrophils are the main source of faecal S100A12.
The clinical disease activity indices and endoscopic scores, hindered by inaccuracies due to subjective components, are too indistinct to reflect inflammatory activity in chronic IBD and cannot provide precise information about the patient status. Endoscopic and radiological procedures are too invasive, time-consuming or expensive for routine use, or carry risk of radiation exposure. Serological markers (e.g., CRP, ESR) reflect the presence and intensity of a systemic inflammation and are not specific for intestinal inflammatory disease. Whereas most serological biomarkers are of limited use, faecal markers of neutrophil activity can indicate intestinal inflammation. Once bacterial enteritis is ruled out, faecal S100A12 may be an excellent non-invasive marker of IBD activity superior to other biomarkers including faecal Calprotectin. Faecal Calprotectin being derived from monocytes and potentially from epithelial cells is less specific for infiltrating neutrophils.
Faecal S100A12 (Calgranulin C) is a novel non-invasive reliable reproducible surrogate biomarker which strongly correlated with inflammation score with the potential to discriminate chronic IBD with or without active mucosal lesions from those with IBS or healthy control, with superior sensitivity, specificity and diagnostic accuracy to other inflammatory biomarkers including fecal Calprotectin. It could be an adjunctive tool in overall evaluation of patients with nonspecific symptoms and as a practicable objective diagnostic tool in those with IBD. This neutrophil-derived S100A12 protein can significantly improve arsenal of non-invasive biomarkers of intestinal inflammation.
Further longitudinal studies are required in the future to consolidate the promising initial data, improve our knowledge about the biology of S100 proteins and determine the value of faecal S100A12 in diagnosis, monitoring of inflammation and prediction of the disease course in other GI disorders.
Ajaj, W., T.C. Lauenstein, J. Langhorst, C. Kuehle and M. Goyen et al
Small bowel hydro-MR imaging for optimized ileocecal distension in Crohn's disease: Should an additional rectal enema filling be performed? J. Magnetic Resonance Imag., 22: 92-100.CrossRef | PubMed | Direct Link |
Best, W.R., J.M. Becktel, J.W. Singleton and F. Kern Jr., 1976.
Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology, 70: 439-444.PubMed |
Brignola, C., G.A. Lanfranchi, M. Campieri, G. Bazzocchi and M. Devoto et al
Importance of laboratory parameters in the evaluation of Crohn's disease activity. J. Clin. Gastroenterol., 8: 245-248.PubMed |
Campeotto, F., M.J. Butel, N. Kalach, S. Derrieux and C. Aubert-Jacquin et al
High faecal calprotectin concentrations in newborn infants. Arch. Dis. Childhood-Fetal Neonatal Edn., 89: F353-F355.CrossRef | Direct Link |
Costa, F., M.G. Mumolo, L. Ceccarelli, M. Bellini and M.R. Romano et al
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut, 54: 364-368.CrossRef | PubMed | Direct Link |
Dabritz, J., J. Musci and D. Foell, 2014.
Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J. Gastroenterol., 20: 363-375.CrossRef | PubMed | Direct Link |
Daperno, M., G. D'Haens, G. van Assche, F. Baert and P. Bulois et al
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest. Endosc., 60: 505-512.CrossRef | Direct Link |
De Jong, N.S., S.T. Leach and A.S. Day, 2006.
Fecal S100A12: A novel noninvasive marker in children with Crohn's disease. Inflamm. Bowel Dis., 12: 566-572.PubMed |
Dixon, M.F., R.M. Genta, J.H. Yardley and P. Correa, 1996.
Classification and grading of gastritis: The updated Sydney system. Am. J. Surg. Pathol., 20: 1161-1181.Direct Link |
Donato, R., 2003.
Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech., 60: 540-551.CrossRef | Direct Link |
Manolakis, A.C., A.N. Kapsoritakis, E.K. Tiaka and S.P. Potamianos, 2011.
Calprotectin, calgranulin C and other members of the s100 protein family in inflammatory bowel disease. Digest. Dis. Sci., 56: 1601-1611.CrossRef | PubMed | Direct Link |
Marsh, M.N., 1992.
Gluten, major histocompatibility complex and the small intestine: A molecular and immunobiologic approach to the spectrum of gluten sensitivity (celiac sprue). Gastroenterology, 102: 330-354.PubMed |
Niederau, C., F. Backmerhoff and B. Schumacher, 1997.
Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology, 44: 90-107.PubMed |
Nielsen, O.H., B. Vainer, S.M. Madsen, J.B. Seidelin and N.H. Heegaard, 2000.
Established and emerging biological activity markers of inflammatory bowel disease. Am. J. Gastroentrol., 95: 359-367.PubMed |
Oberhuber, G., 2000.
Histopathology of celiac disease. Biomed. Pharmacother., 54: 368-372.CrossRef | Direct Link |
Papp, M., G.L. Norman and I. Altorjay, 2007.
Utility of serological markers in inflammatory bowel diseases: Gadget or magic? World J. Gastroenterol., 13: 2028-2036.PubMed |
Pardi, D.S. and W.J. Sandborn, 2005.
Predicting relapse in patients with inflammatory bowel disease: What is the role of biomarkers? World J. Gastroenterol., 13: 2028-2036.Direct Link |
Peterson, C.G., E. Eklund, Y. Taha, Y. Raab and M. Carlson, 2002.
A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: Establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am. J. Gastroenterol., 97: 1755-1762.CrossRef | PubMed |
Rachmilewitz, D., 1989.
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ, 298: 82-86.PubMed | Direct Link |
Roth, J., T. Vogl, C. Sorg and C. Sunderkotter, 2003.
Phagocyte-specific S100 proteins: A novel group of proinflammatory molecules. Trends Immunol., 24: 155-158.CrossRef | PubMed |
Salama, I., P.S. Malone, F. Mihaimeed and J.L. Jones, 2008.
A review of the S100 proteins in cancer. Eur. J. Surg. Oncol., 34: 357-364.CrossRef | PubMed | Direct Link |
Santamaria-Kisiel, L., A.C. Rintala-Dempsey and G.S. Shaw, 2006.
Calcium-dependent and -independent interactions of the S100 protein family. Biochem. J., 396: 201-214.
Moskaluk, C.A., M.K. Abdrabbo, J. Harper, C. Yoshida, G.J. Riggins, H.F. Frierson and S.M. Powell, 2002.
Gastric cancers overexpress S100A Calcium-binding proteins. Cancer Res., 62: 6823-6826.Direct Link |
Foell, D., M. Frosch, C. Sorg and J. Roth, 2004.
Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin. Chimica Acta, 344: 37-51.CrossRef |
Foell, D., D. Kane, B. Bresnihan, T. Vogl and W. Nacken et al
Expression of the Pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology, 42: 1383-1389.CrossRef |
Foell, D., T. Kucharzik, M. Kraft, T. Vogl, C. Sorg, W. Domschke and J. Roth, 2003.
Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut, 52: 847-853.CrossRef |
Foell, D. and J. Roth, 2005.
S100 proteins in monitoring inflammation: The importance of a gold standard and a validated methodology. J. Immunol., 175: 3459-3460.
Foell, D., H. Wittkowski and J. Roth, 2009.
Monitoring disease activity by stool analyses: From occult blood to molecular markers of intestinal inflammation and damage. Gut, 58: 859-868.CrossRef |
Foell, D., H. Wittkowski, T. Vogl and J. Roth, 2007.
S100 proteins expressed in phagocytes: A novel group of damage associated molecular pattern molecules. J. Leukoc. Biol., 81: 28-37.CrossRef | PubMed |
Hanauer, S.B., 2006.
Inflammatory bowel disease: Epidemiology, pathogenesis and therapeutic opportunities. Inflamm. Bowel Dis., 12: S3-S9.CrossRef |
Hofmann, M.A., S. Drury, C. Fu, W. Qu and A. Taguchi et al
RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell, 97: 889-901.CrossRef |
Jelsness-Jorgensen, L.P., T. Bernklev and B. Moum, 2013.
Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol. Res. Pract.,CrossRef |
Judd, T.A., A.S. Day, D.A. Lemberg, D. Turner and S.T. Leach, 2011.
Update of fecal markers of inflammation in inflammatory bowel disease. J. Gastroenterol. Hepatol., 26: 1493-1499.CrossRef |
Kaiser, T., J. Langhorst, H. Wittkowski, K. Becker and A.W. Friedrich et al
Faecal S100A12 as a Non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut, 56: 1706-1713.CrossRef |
Langhorst, J., S. Elsenbruch, T. Mueller, A. Rueffer, G. Spahn, A. Michalsen and G.J. Dobos, 2005.
Comparison of 4 neutrophil‐derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm. Bowel Dis., 11: 1085-1091.CrossRef |
Schmidt, A.M., S. du Yan, S.F. Yan and D.M. Stern, 2001.
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest., 108: 949-955.CrossRef |
Schroder, O., M. Naumann, Y. Shastri, N. Povse and J. Stein, 2007.
Prospective evaluation of faecal neutrophil‐derived proteins in identifying intestinal inflammation: Combination of parameters does not improve diagnostic accuracy of calprotectin. Alimentary Pharmacol. Ther., 26: 1035-1042.CrossRef |
Seibold, F., O. Stich, R. Hufnagl, S. Kamil and M. Scheurlen, 2001.
Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: A family study. Scandinavian J. Gastroenterol., 36: 196-201.CrossRef |
Seibold, F., P. Weber, R. Klein, P.A. Berg and K.H. Wiedmann, 1992.
Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut, 33: 657-662.CrossRef |
Sherwood, R.A., 2012.
Faecal markers of gastrointestinal inflammation. J. Clin. Pathol., 65: 981-985.CrossRef |
Sugi, K., O. Saitoh, I. Hirata and K.I. Katsu, 1996.
Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: Comparison with other neutrophil-derived proteins. Am. J. Gastroenterol., 91: 927-934.Direct Link |
Tibble, J.A., G. Sigthorsson, R. Foster, I. Forgacs and I. Bjarnason, 2002.
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology, 123: 450-460.CrossRef |
Vogl, T., C. Propper, M. Hartmann, A. Strey and K. Strupat et al
S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J. Biol. Chem., 274: 25291-25296.Direct Link |
Declaration of Helsinki: Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, World Medical Association (WMA), Helsinki, Finland.
Xiang, J.Y., Q. Ouyang, G.D. Li and N.P. Xiao, 2008.
Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J. Gastroenterol., 14: 53-57.Direct Link |
Vermeire, S., G. van Assche and P. Rutgeerts, 2006.
Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut, 55: 426-431.CrossRef |